Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 10, 2017

OncoArendi to evaluate OATD-01 in Phase I trial for asthma

Polish biopharmaceutical company OncoArendi Therapeutics is set to conduct a Phase I clinical trial of its lead drug candidate OATD-01 to treat patients suffering from asthma.

Polish biopharmaceutical company OncoArendi Therapeutics is set to conduct a Phase I clinical trial of its lead drug candidate OATD-01 to treat patients suffering from asthma.

The German Federal Institute for Drugs and Medical Devices (BfArM) has approved the trial.

OATD-01 is being developed as a potent dual inhibitor of acidic mammalian chitinase (AMCase) and chitotriosidase (CHIT1).

The randomised, double-blind, dose-escalation Phase I trial will investigate the safety, tolerability and pharmacokinetics of OATD-01 in 48 healthy male subjects enrolled in multiple dose cohorts within single dose-range.

OncoArendi Therapeutics president and CEO Marcin Szumowski said: “The initiation of the Phase I clinical trial of OATD-01 is a major milestone, not only for the programme, but also for the advancement of an entirely new class of drugs.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
“The initiation of the Phase I clinical trial of OATD-01 is a major milestone, not only for the programme, but also for the advancement of an entirely new class of drugs.”

“It is also a significant milestone in the development of OncoArendi as it has now become a clinical-stage biotechnology company.”

The safety and tolerability of the drug candidate will be measured as primary outcome measures of the trial through assessment of nature and frequency of adverse events (AEs), laboratory assessments and electrocardiogram (ECG).

OncoArendi Therapeutics Development vice-president Stanislaw Pikul said: “With the recent discovery of the significant anti-fibrotic activity of OATD-01, we are very excited about the clinical prospects of the chitinase inhibitors in treatment of not only asthma but also other interstitial lung diseases, including idiopathic pulmonary fibrosis or sarcoidosis.”

Results obtained from the Phase I trial are expected to aid in designing the subsequent trial planned for next year to assess various increasing doses of OATD-01.


Image: Obstruction of the lumen of the bronchiole in an asthma patient. Photo: courtesy of Yale Rosen/Flickr.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU